Santen Corporate (EN)

2026 IR News

RSS

IR News

Santen New Drug Application Filing Accepted for Review in China for STN1012700 (Atropine Sulfate Ophthalmic Solution 0.025%), an Ophthalmic Solution to Slow the Progression of Myopia
Notice on the Disposal of Treasury Shares for the Post-delivery Type Performance-Linked Stock Remuneration Plan
Santen Launches Rhopressa® Ophthalmic Solution 0.02% in Japan, a Treatment for Glaucoma and Ocular Hypertension
Summary of Consolidated Financial Results for the Three Months Ended June 30, 2026 (IFRS)
Santen Joins Inaugural Global Summit for Eye Health as High-Impact Partner
Santen and KYORIN announce joint marketing agreement in Japan for allergic conjunctivitis treatment Alesion® Eyelid Cream 0.5%
Corporate Governance Report
Santen Obtains Marketing Approval in the Philippines for STN1012700 (Ryjusea 0.25mg/mL Ophthalmic Solution), an Ophthalmic Solution to Slow the Progression of Myopia — First Approval in Santen’s Asia Business Region
Santen Obtains Manufacturing and Marketing Approval in Japan for Rhopressa® Ophthalmic Solution 0.02%, a Treatment for Glaucoma and Ocular Hypertension
Summary of Consolidated Financial Results for the Year Ended March 31, 2026 (IFRS)
Santen China Signs Exclusive Distribution and Promotion Agreement for Five Marketed Glaucoma Eyedrops Products in the Chinese Mainland
Santen to Launch UPNEEQ® Mini Ophthalmic Solution 0.1%, a Treatment for Acquired Blepharoptosis
Notice of Board of Director and Corporate Auditor Nominations
Summary of Consolidated Financial Results for the Nine Months Ended December 31, 2025 (IFRS)
Launch of Aflibercept kit for IVT inj. 40 mg/mL Bayer